U.S. stock futures were higher this morning, with the Dow futures gaining over 300 points on Wednesday.
Shares of Sarepta Therapeutics, Inc. SRPT fell sharply in today's pre-market trading after the company reported a first-quarter adjusted EPS miss.
Therapeutics reported quarterly losses of $3.42 per share, which missed the analyst consensus estimate of losses of 95 cents. Quarterly revenue came in at $744.86 million, which beat the consensus estimate of $683.36 million.
Sarepta Therapeutics lowered its fiscal 2025 revenue to a new range of $2.3 billion to $2.6 billion.
Sarepta Therapeutics shares tumbled 20.6% to $37.10 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
- Vestis Corporation VSTS fell 25.7% to $6.47 in pre-market trading after the company reported worse-than-expected quarterly financial results.
- Upstart Holdings, Inc. UPST fell 16.2% to $43.09 in pre-market trading after the company issued second-quarter sales guidance below estimates.
- Apellis Pharmaceuticals, Inc. APLS dipped 13.6% to $16.53 in pre-market trading following first-quarter results.
- Revolve Group, Inc. RVLV fell 10.8% to $16.90 in today's pre-market trading after the company reported downbeat quarterly sales.
- The Hackett Group, Inc. HCKT dipped 8.9% to $23.69 in pre-market trading after the company issued weak outlook for the second quarter.
- RXO, Inc. RXO fell 7.6% to $12.70 in pre-market trading.
- Marvell Technology, Inc. MRVL dipped 7% to $56.94 in pre-market trading after the company postponed its Investor Day amid uncertainty.
- Lantheus Holdings, Inc. LNTH declined 6.5% to $98.06 in pre-market trading after the company posted downbeat first-quarter results and lowered its FY25 forecast.
- Mercury Systems, Inc. MRCY fell 5.7% to $47.54 in pre-market trading following weaker-than-expected quarterly earnings.
- Arista Networks Inc ANET dipped 5.3% to $86.00 in pre-market trading following downbeat quarterly sales.
Now Read This:
Photo via Shutterstock
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.